Determinants of Changes in Linear Growth and Body Composition in Incident Pediatric Crohn's Disease

Department of Pediatrics, The Children's Hospital of Philadelphia, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.
Gastroenterology (Impact Factor: 16.72). 08/2010; 139(2):430-8. DOI: 10.1053/j.gastro.2010.04.044
Source: PubMed


Pediatric Crohn's disease (CD) is associated with growth, lean mass (LM), and fat mass (FM) deficits. This study assessed and identified determinants of changes in height and body composition in children with CD following.
Whole-body LM and FM were assessed using dual-energy x-ray absorptiometry in 78 CD subjects at diagnosis, 6, 12, and a median of 43 months (range, 24-63) later. Race- and sex-specific Z scores for lean mass (LM-ht-Z) and fat mass (FM-ht-Z) relative to height were derived using reference data in >900 controls. Serum cytokines and growth factors were measured, and quasi-least squares regression was used to identify determinants of changes in height and body composition.
LM-ht-Z and FM-ht-Z (both P<.005) improved significantly after diagnosis; however, female patients had persistent LM deficits vs controls (-0.50+/-1.02, P<.05). Serum interleukin-6, tumor necrosis factor-alpha, and lipopolysaccharide binding protein decreased significantly (all P<.001). Greater increases in LM-ht-Z were associated with infliximab therapy (P<.05), increases in albumin (P<.001) and decreases in erythrocyte sedimentation rate (P<.05), interleukin-6 (P<.005), and lipopolysaccharide binding protein (P<.05). Greater increases in FM-ht-Z were associated with glucocorticoid, methotrexate, and infliximab therapy, and increases in albumin (P<.05) and growth hormone binding protein (P<.05). Overall, height-Z did not improve; however, greater increases in insulin-like growth factor-1 (P<.05) and decreases in tumor necrosis factor-alpha (P<.05), interleukin-6 (P<.05), and lipopolysaccharide binding protein (P<.05) levels were associated with increases in height-Z.
Immune-mediated mechanisms contribute to growth and body composition deficits in CD. Therapies should target these deficits.

Download full-text


Available from: Justine Shults, Mar 20, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: The photolysis of two antibacterial compounds, sulfamethoxazole and trimethoprim, was studied in wastewater effluent. The rate of loss of sulfamethoxazole was enhanced in wastewater effluent due to indirect photolysis reactions, specifically reactions with hydroxyl radicals and triplet excited state effluent organic matter. Photolysis in the presence of natural organic matter, however, did not lead to enhanced degradation of sulfamethoxazole. Trimethoprim was also found to be susceptible to indirect photolysis in wastewater effluents, with hydroxyl radical and triplet excited effluent organic matter being the responsible species. Deoxygenation of solutions led to more rapid direct photolysis of sulfamethoxazole and trimethoprim, indicating that direct photolysis proceeds through a triplet excited state, which was verified by demonstrating that trimethoprim is a singlet oxygen sensitizer. In the wastewater effluents tested, photolysis could be apportioned into direct photolysis (48% for sulfamethoxazole, 18% for trimethoprim), reaction with hydroxyl radicals (36% and 62%, respectively) and reaction with triplet excited effluent organic matter (16% and 20%, respectively). These results indicate that allowing photolysis in wastewater stabilization ponds or wastewater treatment wetlands may lead to enhanced pharmaceutical removal prior to discharge and that effluent organic matter has different photoreactivity than natural organic matter.
    No preview · Article · Oct 2010 · Water Research
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To examine exercise capacity in youth with Crohn's disease (CD) and ulcerative colitis (UC). Eleven males and eight females with CD and six males and four females with UC participated. Patients performed standard exercise tests to assess peak power (PP) and mean power (MP) and peak aerobic mechanical power (W(peak)) and peak oxygen uptake (VO(2peak)). Fitness variables were compared with reference data and also correlated with relevant clinical outcomes. Pediatric patients with inflammatory bowel disease had lower PP (∼90% of predicted), MP (∼88% of predicted), W(peak) (∼91% of predicted), and VO(2peak) (∼75% of predicted) compared with reference values. When patients with CD or UC were compared separately to reference values, W(peak) was significantly lower only in the CD group. No statistically significant correlations were found between any exercise variables and disease duration (r = 0.01 to 0.14, P = .47 to .95) or disease activity (r = -0.19 to -0.31, P = .11 to .38), measured by pediatric CD activity index or pediatric ulcerative colitis activity index. After controlling for chronological age, recent hemoglobin levels were significantly correlated with PP (r = 0.45, P = .049), MP (r = 0.63, P = .003), VO(2peak) (r = 0.62, P = .004), and W(peak) (r = 0.70, P = .001). Pediatric patients with inflammatory bowel disease exhibit impaired aerobic and anaerobic exercise capacity compared with reference values.
    Full-text · Article · Dec 2010 · The Journal of pediatrics
  • [Show abstract] [Hide abstract]
    ABSTRACT: Growth failure is common in children with inflammatory bowel disease (IBD), mainly those with Crohn's disease (CD). The prevalence of growth failure varies in different cohorts, mainly due to the heterogeneity of the population treated by the reporting centers (primary vs. referral), but can be as high as 40% of the cases. Factors related to growth impairment in CD include low dietary intake, stool loss, increased energy and nutrient requirements, the use of medications (for example, steroids interfere with the IGF-1 axis), disease activity (the effect of inflammation on growth), genetic background (parents height), and physical activity. In animals, malnutrition, genetic polymorphism, elevated pro inflammatory cytokines, and exposure to lipopolysaccharide are involved in growth impairment in IBD, while malnutrition, genetic polymorphism and increased inflammation have been shown to be associated with growth impairment in humans. Exclusive enteral nutrition (EEN) is the preferred first line treatment in CD. EEN induces remission, prolongs remission and affects growth failure via its effect on malnutrition and inflammation. However, similar to drug treatment, EEN effect on growth failure is limited, most probably due to incomplete control of inflammation. Children with IBD should be assessed for growth on diagnosis and on each follow-up visit. New nutritional strategies, identification of genetic polymorphisms that respond to EN, and methods to increase lean body mass (physical activity) are needed in order to improve growth in our IBD patients.
    No preview · Article · Dec 2010 · Journal of pediatric gastroenterology and nutrition
Show more